Drugs / Anti-CD20 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02737085 | Mar 2016 → Dec 2019 | diffuse large B-cell lymphoma | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD20 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02737085 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T(CAR-T) cells” NCT02737085 ↗ |